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Background: Osteogenesis imperfecta (OI) comprises a clinically and genetically heterogeneous group of
connective tissue disorders, characterized by low bone mass, increased bone fragility, and blue-gray eye sclera. OI
often results from missense mutations in one of the conserved glycine residues present in the Gly-X-Y sequence
repeats of the triple helical region of the collagen type I α chain, which is encoded by the COL1A1 gene. The aim of
the present study is to describe the phenotype of OI II patient and a novel mutation, causing current phenotype.
Results: We report an undescribed de novo COL1A1 mutation in a patient affected by severe OI. After performing
the whole-exome sequencing in a case parent–child trio, we identified a novel heterozygous c.2317G > T missense
mutation in the COL1A1 gene, which leads to p.Gly773Cys transversion in the triple helical domain of the collagen
type I α chain. The presence of the missense mutation was confirmed with the Sanger sequencing.
Conclusions: Hereby, we report a novel mutation in the COL1A1 gene causing severe, life threatening OI and
indicate the role of de novo mutation in the pathogenesis of rare familial diseases. Our study underlines the
importance of exome sequencing in disease gene discovery for families where conventional genetic testing does
not give conclusive evidence.
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Osteogenesis Imperfecta (OI), or “brittle bone” disease,
is a heritable disorder of collagen type I metabolism with
a generalized involvement of connective tissues. Colla-
gen is the most abundant protein in mammals, consti-
tuting a quarter of the total protein weight [1]. Collagens
are grouped into families based on their structural and
functional features. Type I collagen is the major protein
in bone, skin, tendon, ligament, sclera and cornea
tissues, blood vessels, and hollow organs ENREF 2 [2].
OI is mostly caused by quantitative or qualitative colla-
gen type I defects. The condition is characterized by low
bone mass, bone fragility, and often short stature.* Correspondence: Katre.maasalu@kliinikum.ee
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unless otherwise stated.Extraskeletal manifestations may include blue-gray eye
sclera and dental abnormalities. The clinical severity var-
ies widely from nearly asymptomatic forms with a mild
predisposition to fractures, normal stature, and normal
lifespan to profoundly disabling and even lethal [3, 4].
The pathogenetic approach to OI is changed with the
recent identification of non-collagenous genes, mutations
in which may cause OI. In general, a clear genotype-
phenotype correlation does not exist. General rules for
genotype-phenotype correlations have been published only
in COL1A1/2-related OI [5]. Approximately 90 % of indi-
viduals affected with OI are heterozygous for a causative
variant in one of the two genes, COL1A1 or COL1A2,
which encode the pro-1(I) and pro-2(I) chains of type I
procollagen, respectively [6].
The proportion of cases caused by a de novo COL1A1
or COL1A2 mutation varies according to the severity of
the disease. Approximately 60 % of cases of classic non-l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with normal sclerae, virtually 100 % of perinatally lethal
OI, and close to 100 % of progressively deforming OI
are caused by de novo mutations [7, 8].
In 1979, a classification of OI was introduced by David
Sillence and the disease was divided into four types with
a wide spectrum of clinical features, where OI type II is
the most severe and prenatally lethal form of the dis-
order [9]. Initial classification, based on clinical and
histological manifestations, was extended into five dis-
tinct types of OI [10]. By now, genetic studies described
various OI phenotypes, and genetic OI classification is
broadened up to 15 different OI types, according to the
affected gene. In addition to collagen genes, OI is caused
by mutations in the CRTAP (OI VII), LEPRE 1 (OI VIII),
BMP1 (OI XIII), TMEM38B (OI XIV), IFITM5 (OI V),
SERPINH1 (OI X), WNT1 (OI XV), SP7 (OI XII), PPIB
(OI IX), SERPINF1 (OI VI), FKBP10 (OI XI) genes
[11–14].
In addition to big genotype diversity, the phenotype
manifestations may vary not only among representa-
tives of the same OI type but also among carriers of
the same mutation and even affected members of the
same family. Some of the OI forms represent transi-
tional phenotypes between different forms. Therefore,
the genotype-phenotype relationships and clinical mani-
festations of OI are still difficult to explain.
The aim of present study is to describe the phenotype
of OI II patient, with severe life threatening bone fragility,701 702
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Fig. 1 Pedigree structure of an Estonian family affected with type II OI. DN
proband (716)and report a novel mutation, causing current phenotype.
We strongly believe that new additional information on
current transitional OI form will deepen the understand-
ing of the pathogenesis of the brittle bone disease.
Materials and methods
The Ethics Review Committee on Human Research of
the University of Tartu approved the study and the par-
ticipants, and their legal representatives gave prior con-
sent to participate in the study and publish the results.
Blood samples were obtained from the proband (716),
her brother (715), and parents (710 and 711) from a
family without previous history of OI (Fig. 1). Genomic
DNA was extracted from EDTA-preserved blood accord-
ing to standard high-salt extraction methods and stored
at −80 °C.
The proband (716) was the first child (first pregnancy,
first delivery) of non-consanguineous Estonian parents;
age of the mother and father were 23 and 27 years, re-
spectively. The parents were healthy without history of
chronic or clinically significant diseases.
The girl was born with totally soft skull, the head was
large (diameter 43 cm), and bones in occipital region
were not palpable (skinhead). Her head was flat, being
collapsed from front to back direction. She has exoph-
thalmia and blue sclerae. The newborn had dispropor-
tional growth retardation (limbs > body): short, bowed











Fig. 2 Results of the validation of novel COL1A1 mutation. a The
Integrated Genomics Viewer image corresponding to COL1A1 exon
33–34 de novo variant c.2317G > T (GGC > TGC on „ + “strand).
Genomic coordinates are given according to GRCh37/hg19
reference sequence. b Validation of the c.2317G > T by Sanger
sequencing. Electropherograms of the index patient (716), her
mother (711), father (710). Over 10 Gb of sequence was generated
from each individual, resulting in a coverage depth of 84× for both
parents and 87× for an affected child, and an unaffected brother
(715) is shown. C (cytosine) is blue, T (thymine) is red, G (guanine)
is black. The position of the heterozygous c.2317G > T mutation is
marked by an arrow. The mutation is absent in both parents,
confirming its de novo occurrence in the proband
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of parietal and mandibular bones were detected in Baby-
gram X-ray investigation on date of birth. All long bones
were extremely osteopenic; she had accordion-type ribs,
and several fractures in different healing stages were de-
tected in every bone. In addition, fresh right humeral
fracture and left tibial fracture were confirmed.
In genetic counseling, at the age of 3 days, the baby
was diagnosed with osteogenesis imperfecta type II
based on clinical signs and X-ray data. As family history
was negative for the OI, de novo autosomal dominant
mutation was suspected.
Exome sequencing
Whole-exome sequencing was performed on an affected
child and both unaffected parents at the NGS core facil-
ity of the Estonian Genome Center, University of Tartu.
Exome capture was performed using the TruSeq Exome
Enrichment kit (Illumina) following the manufacturer’s
protocol. The captured libraries were sequenced with
Illumina HiSeq2000 with 100-bp paired-end reads. Over
10 Gb of sequence was generated from each individual,
resulting in a coverage depth of 84× for both parents
and 87× for an affected child. Sequence reads were
aligned to the human reference genome (hg19, GRCh37)
with the Burrows-Wheeler Aligner (BWA, version 0.6.1)
[15]. Single-nucleotide substitutions and small indel vari-
ants were called with SAM tools (version 0.1.18), Picard
tools (version 1.60), and a Genome Analysis Toolkit
(GATK, version 1.5.21) [16, 17]. Genotypes were called
at all positions with high-quality sequence bases and
filtered to retain SNPs and insertion-deletions with
Phred-like quality scores of at least 20. We focused on
non-synonymous and canonical splice-site variants being
absent from public datasets (including dbSNP135 and
the 1000 Genomes Project) and in-house exome and
full-genome data. We used the PolyPhen-2, SIFT, and
Condel software tools to predict the functional effects of
mutations [18–20]. Mutation analysis was performed
with Sanger sequencing on an affected child (716), on
both parents (710, 711), and an unaffected brother (715).
Results
We studied an Estonian family (Fig. 1) of a patient with
severe OI in order to identify causative mutation for the
disease. Using exome sequencing, we found a novel het-
erozygous G to T transversion in exon 33/34 at the pos-
ition 2317 of the COL1A1 gene. This mutation leads to
the substitution of glycine to cysteine at residue 773 in
the triple helical domain of the alpha-1 chain of type I
collagen. In the other previously known 15 AR OI genes,
no potential pathogenic variants were found. The identi-
fied mutation was absent in both parents, demonstrating
that this variant arose as de novo in the proband. Validationby Sanger sequencing confirmed that the c.2317G > T
(p.Gly773Cys) mutation was present in a heterozygous
state in the index patient only (Fig. 2). This missense
mutation affects a highly conserved amino acid (phyloP
score 5.418), and in silico analysis predicted this variant
to be deleterious. This mutation was not present nei-
ther in the Exome Variant Server of the NHLBI-ESP
database or in the 1000 Genomes database. It was also
not detected in 221 Estonian control exomes and in full
genomes from 87 Estonians.
Discussion
Here, we report a heterozygous p.Gly773Cys mutation in
COL1A1, affecting a highly conserved residue in the
triple helical domain of collagen type I α chain, as a
novel causative variant for severe OI with the lethal out-
come. Therefore, given the large number of different
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relationships and clinical manifestations are difficult to
explain and present report gives additional information
of pathophysiology of OI.
The severity of clinical signs (blue sclerae, totally soft,
large and collapsed head; disproportional growth retard-
ation, short and bowed arms and legs, severe breathing
failure) and clinical findings (extremely osteopenic bones,
several fractures in different healing stages in all bones,
deformities, bone development retention) of our patient
resembles those of the patients described with the lethal
type of OI.
Our study found a novel heterozygous G to T trans-
version in exon at the position 2317 of the COL1A1 gene
(Fig. 3). There is another mutation described in dbSNP
database—rs72651659—at the exact same position, with
G to A substitution that leads to the substitution of
glycine to serine at residue 773. Currently, altogether
756 unique DNA variants (substitutions, insertions,
deletions, insertions/deletions, and duplications) in OI
patients have been identified in the COL1A1 gene, and
the total number of reported variants is 1352 [11]. The
overall pattern of severity of OI phenotypes that result
from glycine substitutions in the triple helical domain of
the a1(I) chain of type I procollagen is not uniform along
the chain. Mutation can be non-lethal, when its position
is smaller or equal to 688. If substitution occurs C-
terminally to 688, its effect is lethal [21]. Approximately
one-third (35.6 %) of all independent glycine substitu-
tions in COL1A1 are reported to result in lethal type of
OI. However, whereas glycine substitutions to valine and
to the charged amino acids (aspartic acid, glutamic acid,
and arginine) are predominantly lethal (reaching up to
73 % of occurrences for valine), substitutions by the
polar residues serine and cysteine have interspersed le-
thal and non-lethal outcomes with a frequency of lethal
cases in ~30 % of occurrences for cysteine [8].
The p.Gly773Cys is located within a long stretch of
helical residues 691–823, in which essentially mostlyFig. 3 The alignment of DNA and protein sequences of COL1A1 gene is illu
position 2317 of the COL1A1 gene leads to Gly773 Cys substitution. At the
known SNP is the G to A transition that leads to Gly773 Ser substitutionlethal substitutions are identified and also corresponds
to Bodian’s “COL1A1 decision tree” about the lethality
of mutation [8, 21, 22]. This region correlates with the
major ligand binding region 2 (MLBR 2) that extends
from helical positions 682–830 in the type I collagen
fibril and includes sites that are crucial for collagen self-
assembly [8]. This region is important also for interac-
tions of collagen monomers or fibrils with α1β1/α2β1
integrins, matrix metalloproteinases (MMPs), fibronec-
tin, and cartilage oligomeric matrix protein [23]. The
Gly773 residue lies within overlapping MMP interaction
domain and cell interaction domain with human type I
collagen fibril and within ligand binding sites for se-
creted protein, acidic, and rich in cysteine (SPARC), fi-
bronectin, and MMP1, 12, and 13 [24]. Therefore,
mutations in this region interfere severely with the func-
tion of protein.
Substitutions of the same glycine residue in COL1A1
often have independent lethal and non-lethal outcomes.
The described p.Gly773Cys mutation was lethal, exclud-
ing possibility that this family manifests OI type III.
Moreover, neighboring Gly to Cys substitutions are
reported to have diverse outcomes. P.Gly770Cys was
reported to cause OI type II with a lethal outcome,
whereas p.Gly788Cys represents a non-lethal variant
causing OI type III/IV [8].Conclusions
The present study describes a de novo p.Gly773Cys mu-
tation in COL1A1 related to the severe OI that gives
additional information of pathophysiology of OI. This
shows that phenotyping together with genotyping is im-
portant to identify special patients and relevant for
counseling of parents.
Our study underlines the importance of exome se-
quencing in disease gene discovery for families where
conventional genetic testing does not give conclusive
evidence.strated. The G to T transversion (red rectangle) in exon 33/34 at the
same position, already known SNP (rs72651659) is located, but the
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